Intuniv is available as 1mg, 2mg, 3mg, and 4mg extended-release tablets The Food and Drug Administration (FDA) has approved a new update to the Intuniv (guanfacine; Shire) labeling regarding ...
Shire announced an FDA approval for Intuniv (guanfacine) Extended Release Tablets yesterday, and is preparing professional advertising efforts for a November launch. Matthew Cabrey, a spokesperson for ...
Intuniv, a once-daily non-stimulant from Shire and Shionogi for adults with attention-deficit/hyperactivity disorder, met its primary endpoint and showed a superior ...
PHILADELPHIA, Feb. 28, 2011 /PRNewswire/ -- Shire plc, (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) ...
Teva was looking to launch its generic version of Intuniv and had filed an abbreviated new drug application (ANDA) with the FDA in 2010. Shire subsequently filed a lawsuit against Teva for ...
Data from a Phase III study evaluating Shire’s Intuniv in Japan in adults with attention deficit hyperactivity disorder indicate that the drug could improve symptoms of the condition in this patient ...
The FDA's approval of Intuniv brings to four the number of drugs for ADHD currently marketed by Shire. (The other three are Adderall XR, Vyvanse and the Daytrana patch.) There are about 11 drugs on ...
NEW ORLEANS, May 21 /PRNewswire-FirstCall/ --Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced new findings on once ...
Patient materials for Shire’s ADHD drug Intuniv presented unsubstantiated effectiveness and superiority claims and downplayed important risk info, said the FDA’s Division of Drug Marketing, ...
WASHINGTON, May 7 -- Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented today at a major scientific meeting findings from analyses of pivotal trial results ...
INTUNIV (guanfacine) 1mg, 2mg, 3mg, 4mg ext-rel tablets by Shire The FDA has approved once-daily Intuniv (guanfacine extended-release tablets, from Shire), a selective alpha-2A adrenergic receptor ...
Takeda Pharmaceutical Co has agreed to pay $1.85 million to settle claims by consumers that its predecessor Shire PLC delayed the launch of a generic version of its ADHD drug Intuniv through an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results